Vontobel Holding Ltd. Has $1.27 Million Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Vontobel Holding Ltd. trimmed its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 18.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,878 shares of the medical research company’s stock after selling 861 shares during the quarter. Vontobel Holding Ltd.’s holdings in Bio-Rad Laboratories were worth $1,274,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Strategic Financial Concepts LLC acquired a new stake in Bio-Rad Laboratories during the fourth quarter valued at approximately $3,561,000. Lecap Asset Management Ltd. acquired a new position in shares of Bio-Rad Laboratories in the 4th quarter worth approximately $510,000. Principal Financial Group Inc. boosted its holdings in shares of Bio-Rad Laboratories by 95.6% in the 3rd quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock worth $14,836,000 after acquiring an additional 21,669 shares in the last quarter. Mawer Investment Management Ltd. boosted its holdings in shares of Bio-Rad Laboratories by 63.0% in the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock worth $72,900,000 after acquiring an additional 84,237 shares in the last quarter. Finally, Verition Fund Management LLC boosted its holdings in shares of Bio-Rad Laboratories by 193.3% in the 3rd quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company’s stock worth $1,161,000 after acquiring an additional 2,287 shares in the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on BIO. Royal Bank of Canada reissued an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday. Wells Fargo & Company reduced their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Finally, Citigroup boosted their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Price Performance

BIO opened at $276.55 on Tuesday. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $387.99. The company has a fifty day simple moving average of $337.34 and a 200 day simple moving average of $335.68. The stock has a market cap of $7.74 billion, a P/E ratio of -10.12 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.33 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.